S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 63,954.71 +0.09%
Next Bullish Trade
Sign in
ARTL

Artelo Biosciences, Inc. ARTL

$1.15 +0.01 (+0.88%)
Neutral · -0.27σ Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · ARTL

Momentum reads · latest daily bar
Last
$1.15
+0.01 (+0.88%)
Mkt cap
$4M
Healthcare
RSI(14)
41.1
neutral
Stochastic %K
66.5
neutral
MFI(14)
37.4
neutral
ADX(14)
21.2
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 — $-0.0B $-0.0B $-0.0B — —
2025-12-31 — $-0.0B $-0.0B $-0.0B — —
2025-09-30 — $-0.0B $-0.0B $-0.0B — —
2025-06-30 — $-0.0B $-0.0B $-0.0B — —
2025-03-31 — $-0.0B $-0.0B $-0.0B — —
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare ARTL vs peers

Line ARTL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing ARTL META×
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP
Verdict
Weighted score 0-100 across 2 tickers · best in green
#2
ARTL
score 31.2
3/5 inputs
Catastrophic momentum score of zero from 97.67% drop from 52-week high obliterates otherwise decent value metrics.
value 50quality 42momentum 0
#1
META
score 85.0
3/5 inputs
Perfect 100 scores in both quality and momentum drive dominance despite missing fundamental data across all categories.
quality 100momentum 100sentiment 50
ARTL
Artelo Biosciences, Inc.
$1.15
+0.88%
Snapshot
Price 1.15
Day % 0.88
1M % -10.85
3M % -76.34
YTD % -69.82
Market cap 4008371.0
ADV ($) 1952642.4595177174
Beta -0.111
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % -2.71
Dist ATR (σ) -0.27
OdysseyHQ grade C
Confluence 2
Valuation
P/E (ttm) —
P/E (fwd) -1.3068181
P/S —
EV/EBITDA —
P/B 0.15099789
FCF yield -0.769
PEG —
Growth
Revenue yoy —
EPS yoy —
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.0
Operating margin 0.0
Net margin 0.0
ROE -3.67695
ROA -0.91327006
Debt / Equity 0.11
Interest cov. -45.49
Technicals
RSI(14) 41.1
MACD signal neutral
vs 50-DMA -20.26
vs 200-DMA -76.75
vs 52w high -97.67
HV-30 56.9
Sentiment
Analyst rec —
Target upside —
Insider buy-sell 90d —
Risk
Short interest 5.6199998
Days to cover 0.67
Next earnings —
Full ARTL dashboard →
META
META
$646.01
-2.79%
Snapshot
Price 646.01
Day % -2.79
1M % 7.63
3M % -4.56
YTD % -0.68
Market cap —
ADV ($) —
Beta —
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 3.85
Dist ATR (σ) 0.91
OdysseyHQ grade C
Confluence 5
Valuation
P/E (ttm) —
P/E (fwd) —
P/S —
EV/EBITDA —
P/B —
FCF yield —
PEG —
Growth
Revenue yoy —
EPS yoy —
FCF yoy —
Revenue trend 8Q
Quality
Gross margin —
Operating margin —
Net margin —
ROE —
ROA —
Debt / Equity —
Interest cov. 74.76
Technicals
RSI(14) 56.8
MACD signal bull
vs 50-DMA 6.86
vs 200-DMA 0.86
vs 52w high -18.87
HV-30 52.2
Sentiment
Analyst rec —
Target upside —
Insider buy-sell 90d -28
Risk
Short interest —
Days to cover —
Next earnings —
Full META dashboard →

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
ARTL ★ $0B — -1.3 — — 0.2 — — — -76.90%
LLY $1,051B 41.5 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 31.8 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.0 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.8 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 1.34%

HolderShares% out
Kathmere Capital Management, Llc 13,250 0.38%
Jane Street Group, LLC 13,079 0.38%
Vanguard Capital Management LLC 10,129 0.29%
Vanguard Fiduciary Trust Co 3,139 0.09%
Citigroup Inc. 3,076 0.09%
Tower Research Capital LLC (TRC) 2,826 0.08%
Altshuler Shaham Ltd 889 0.03%
Rothschild Investment LLC 2 —
Clear Street Group Inc. 100 —
Osaic Holdings Inc. 1 —

Insider activity · 90d

No insider trades for ARTL in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$—
Mean
$—
High
$—
Analysts
—
Recommendation distribution · period 2026-07-01
3
1
2
Revision trend (2026-04-01 → 2026-07-01): net -3 → -3 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-17 FORM 8-K view ·
DEF 14A 2026-06-05 DEF 14A view ·
8-K 2026-05-27 FORM 8-K view ·
8-K 2026-05-15 FORM 8-K view ·
10-Q 2026-05-14 FORM 10-Q view ·
S-1 2026-04-07 FORM S-1 view ·
8-K 2026-04-07 FORM 8-K view ·
8-K 2026-03-30 FORM 8-K view ·
8-K 2026-03-26 FORM 8-K view ·
S-1 2026-03-24 FORM S-1 view ·
S-1 2026-03-20 FROM-S-1 view ·
8-K 2026-03-18 FORM 8-K view ·
8-K 2026-03-17 FORM 8-K view ·
8-K 2026-03-06 FORM 8-K view ·
10-K 2026-02-24 FORM 10-K view ·
8-K 2026-02-05 FORM 8-K view ·
8-K 2026-02-05 FORM 8-K view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
8-K 2026-01-30 FORM 8-K view ·
8-K 2026-01-16 FORM 8-K view ·
8-K 2026-01-02 FORM 8-K view ·
DEF 14A 2025-12-11 DEF 14A view ·
8-K 2025-11-25 FORM 8-K view ·
S-1 2025-11-17 FORM S-1 view ·
8-K 2025-11-14 FORM 8-K view ·
10-Q 2025-11-12 FORM 10-Q view ·
8-K 2025-10-31 FORM 8-K view ·
4 2025-10-30 FORM 4 view ·
4 2025-10-30 FORM 4 view ·
4 2025-10-30 FORM 4 view ·
8-K 2025-10-27 FORM 8-K view ·
8-K 2025-10-17 FORM 8-K view ·
8-K 2025-10-01 FORM 8-K view ·
8-K 2025-09-15 FORM 8-K view ·
8-K 2025-09-10 FORM 8-K view ·
8-K 2025-09-05 FORM 8-K view ·
8-K 2025-09-03 FORM 8-K view ·
8-K 2025-08-29 FORM 8-K view ·
8-K 2025-08-20 FORM 8-K view ·
10-Q 2025-08-13 FORM 10-Q view ·
DEF 14A 2025-08-07 DEF 14A view ·
8-K 2025-08-07 FORM 8-K view ·
8-K 2025-08-04 FORM 8-K view ·
8-K 2025-07-18 FORM 8-K view ·
S-1 2025-07-11 FORM S-1 view ·
8-K 2025-07-11 FORM 8K view ·
4 2025-07-07 PRIMARY DOCUMENT view ·
8-K 2025-06-26 FORM 8-K view ·
8-K 2025-06-13 FORM 8-K view ·
8-K 2025-05-23 FORM 8-K view ·
10-Q 2025-05-13 FORM 10-Q view ·
4 2025-05-05 FORM 4 view ·
4 2025-05-05 FORM 4 view ·

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Options picks · ARTL

ITM + OTM ideas from the latest scan

Loading…

Congress trades · ARTL

STOCK Act disclosures

Loading…

SEC filings & insiders · ARTL

EDGAR · live

Loading…

Holders · ARTL

Institutions & insider activity

Loading…